Randomised Proteomic Stratified Phase III Study of Second Line Erlotinib Versus Chemotherapy in Patients with Inoperable Non-Small Cell Lung Cancer (PROSE)
PROSE confirms VeriStrat can predict differential treatment outcomes in 2nd line advanced NCLSC patients.
Data confirms that the blood-based protein diagnostic is predictive of differential treatment outcomes between two types of therapies for 2nd line NSCLC.